A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
← catalyst calendarNCT07647510 · readout ≤ 864 d
Sponsored by Dianthus Therapeutics (industry) · DNTH — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
195estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myasthenia Gravis, Generalized
Interventions
- Drug: Claseprubart — also filed as DNTH103
- Drug: Placebo
- Combination product: Claseprubart
- Combination product: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score
measured Baseline (Day 1) to Week 17
Permalink · DNTH's whole pipeline · Catalyst calendar · Every registered study · What changed